7 Stocks the Market Is Sorting Out Today

The 10-year Treasury is sitting around 4.57%. Chips are getting hit. Oil is climbing. Healthcare is doing what it always does when macro uncertainty peaks — it hides in plain sight. Seven names worth your attention this morning.

QUALCOMM ($QCOM) — Edge AI Under Pressure

QCOM is trading around $203–$205 today after a volatile stretch. Earlier this week the stock dropped roughly 6–8% on concerns about ByteDance building custom ASICs — a move that rattled the semiconductor sector broadly. The reaction felt outsized.

Here is what matters. Qualcomm is not a data center chip story. It is an edge AI story — smartphones, automotive, IoT, and the growing class of connected devices that actually need on-device intelligence. The QCT segment, which covers integrated circuits and system software for mobile and edge computing, is structurally different from the server hardware names that have absorbed the bulk of export control risk. That distinction is getting lost in the momentum selling.

In fiscal year 2025, Qualcomm posted revenue of $44.28 billion, up 13.7% year over year. Last quarter came in at $2.65 EPS against a $2.56 estimate — a 3.6% beat. JPMorgan recently raised its price target to $265 from $160 and placed the stock on positive catalyst watch ahead of the June 24 investor day. Nvidia CEO Jensen Huang publicly endorsed the stock this week, which is worth noting even if you discount it appropriately.

The 52-week range runs $121.99 to $259.92. Revenue growth is projected at 10–12% for 2026. The argument for buying the weakness here is not that the AI trade is perfect — it is that Qualcomm’s primary exposure is to device-level AI, which is less vulnerable to the export restrictions hitting traditional server hardware. Whether that distinction holds as sentiment shifts is the question to watch at the June 24 investor day.

ELI LILLY ($LLY) — Demand That Does Not Care About CPI

LLY closed around $1,144 Monday and is hovering just above that level this morning. The stock jumped roughly 4% earlier this week on new Phase 3 data from the American Diabetes Association’s 86th Scientific Sessions in New Orleans — and the reaction was deserved.

The data package was significant. Retatrutide, Lilly’s next-generation GIP/GLP-1/glucagon triple agonist, showed substantial weight loss alongside improvements in knee osteoarthritis pain, sleep apnea, and type 2 diabetes. Foundayo — the company’s oral GLP-1 that can be taken without food or water restrictions — outperformed oral semaglutide on both A1C reduction and relative weight loss at 52 weeks in the ACHIEVE program. These are not incremental results.

In 2025, Lilly’s revenue was $65.18 billion, up 44.7% year over year. Earnings grew 94.9%. The 12-month analyst consensus target sits around $1,215, with an average “Buy” rating across 31 analysts. Management has guided for up to five approved obesity medicines by end of decade.

The part people skip: GLP-1 demand does not move with consumer sentiment surveys or CPI prints. People who need Zepbound or Mounjaro still need them when gasoline is expensive and confidence is low. That is the defensive growth argument — not that the stock is cheap, but that the revenue base is structurally insulated from the macro noise dominating everything else right now.

CISCO ($CSCO) — Enterprise Infrastructure With Real Cash Flow

Cisco is trading around $119–$120, down modestly from its recent 52-week high of $130 after a broader tech selloff. CSCO has surged roughly 87–93% over the past year, driven by enterprise AI infrastructure demand and a successful pivot away from pure hardware into software and subscription models.

Bank of America raised its price target to $135 with a Buy rating. JP Morgan maintains a Buy. The analyst consensus across 26 analysts is Buy, with a 12-month target of $126.50. Revenue is recurring, the dividend yield is roughly 1.3%, and the business — routers, switches, cybersecurity, the WEBEX collaboration suite — serves the enterprise and government clients who do not turn off infrastructure spending when macro conditions soften.

What is interesting here is the Cisco Live 2026 announcements: the company unveiled its unified Cloud Control AI platform, expanded its cybersecurity portfolio, and deepened its partnership with NetApp on AI-ready infrastructure. These are not defensive moves — they are offensive positioning at a time when speculative chip names are absorbing most of the volatility.

Slight tangent, but it matters — Cisco climbed from roughly $77 in late March to $120+ in early June. That is a 54% move in one quarter. The stock is not a sleeper anymore. The question now is whether the AI networking cycle has further to run or whether valuation becomes a constraint as the 10-year holds above 4.5%.

EXXONMOBIL ($XOM) — The Iran Risk Premium Is Still Live

XOM is trading around $148–$150 today. Brent crude spiked to $96.77 and WTI climbed to $93.48 earlier this week after Iran suspended nuclear negotiations — a sharp reversal from the brief optimism around a potential deal. The stock moved 2.9% off those headlines and is consolidating near current levels.

The macro driver here is straightforward. The U.S.-Iran conflict has pushed crude from roughly $70 to the low-to-mid $90s since it began in late February. ExxonMobil’s upstream operations benefit directly from sustained prices at this level. Q1 2026 EPS came in at $1.16 against a $0.98 estimate — a 12.6% beat. Revenue hit $85.14 billion versus an $81.24 billion expectation. Record 2025 output near 4.7 million oil-equivalent barrels per day, Guyana production running at record levels, and Golden Pass LNG adding U.S. export capacity are all structural positives.

Analyst targets: Barclays at $182 (Overweight), Mizuho raised its target following oil price outlook revisions, and the broad consensus across 25 analysts is Buy with a 12-month target near $169.91. The 52-week range is $105.53 to $176.41 — meaning there is room on both ends depending on how the geopolitical situation resolves.

The risk is real and worth stating plainly: XOM has become a direct proxy for Middle East geopolitics. Any genuine ceasefire or diplomatic breakthrough unwinds the war premium quickly. One Iran headline reset the trade sharply in both directions this week. As an upstream producer benefiting from structural inflation in energy inputs, XOM is currently the most direct macro hedge available in equities — but it requires holding through the headline volatility.

ORACLE ($ORCL) — Earnings Tonight, Backlog Already on Record

Oracle reports Q4 FY2026 results tonight after the close. The stock is trading around $206 today, having pulled back roughly 13% from recent highs despite a 42% surge since the March earnings call. The market wants proof — and tonight is where Lilly gets to provide it or explain the gap.

The setup is unusual. Oracle holds a $553 billion remaining performance obligation backlog — roughly eight times annual revenue — with a substantial portion tied to a multi-year AI infrastructure deal with OpenAI as part of the Stargate initiative. Cloud revenue grew 44% year over year to $8.9 billion in Q3. Management guided Q4 constant-currency revenue growth of 18–20%. The consensus estimate is approximately $19.1 billion in revenue and $1.96 EPS.

TD Cowen maintained Buy and lifted its target to $300 from $250. The 10-year at 4.57% is a real headwind for any high-multiple growth stock — but Oracle’s backlog provides a degree of revenue visibility that most growth companies simply do not have. The question is not whether the contracts exist. It is whether Oracle can build the data center capacity fast enough to monetize them. The company has secured 10 gigawatts of power for its data center pipeline over three years and added 400 MW of new capacity in Q3 alone.

Tonight’s FY2027 guidance is the binary event, not the Q4 EPS figure. What comes out of the earnings call in terms of backlog conversion pace, capital spending trajectory, and cloud growth acceleration will likely move the stock more than whether it beats by a few cents. Watch the guidance range carefully.

MASTERCARD ($MA) — Volume Business in a Currency-Degrading World

MA is trading around $491, well off its 52-week high of $601.77. The stock has a 52-week low of $464.52, meaning it is not far above its floor. Analyst consensus is Strong Buy across 39 analysts, with a 12-month price target of approximately $647 — roughly 32% implied upside from here.

Q1 2026 results were strong: net revenue up 15.8% year over year, adjusted EPS up 23.3%, operating margin at 60.8%, value-added services growing 22%. Mastercard has beaten consensus for 20 consecutive quarters. In 2025, revenue hit $32.79 billion, up 16.4%.

What makes Mastercard relevant in this specific macro moment is what it actually is — a toll booth on global transaction volume. It does not carry credit risk. It earns fees on every swipe, tap, and digital transfer across more than 200 countries in over 150 currencies. When domestic purchasing power weakens, consumers do not stop spending — they spend differently, often internationally. That cross-border transaction flow is where Mastercard’s economics are strongest.

Forward P/E around 23.9 sits below its 10-year average. The company is actively moving into stablecoins, agentic commerce, and real-time cross-currency rails through its BVNK acquisition. Consumer sentiment at record lows is a headline risk — but Mastercard’s revenue base is volume, not confidence. Those are different things.

ZOETIS ($ZTS) — Beaten Down, Not Broken

This one requires honesty upfront. ZTS dropped 21.5% on May 7 after Q1 2026 results showed flat organic revenue growth, a miss on EPS, and — more damaging — sharply reduced full-year guidance. The company’s Librela canine pain treatment, a key growth driver, has faced slowing veterinarian adoption following FDA safety warnings regarding neurological complications. Simparica Trio is losing market share to lower-priced competition. Argus downgraded the stock to Hold. Multiple shareholder lawsuits have been filed.

The stock is now trading around $75–$79, down more than 50% from its 52-week high of $172. That is a significant reset.

Here is what has not changed. Zoetis remains the world’s largest animal health company, serving companion animals and livestock across more than 100 countries. Its product portfolio spans parasiticides, vaccines, dermatology, oncology pain, and diagnostics. The companion animal market is structurally non-discretionary — pet owners do not stop treating sick animals because consumer sentiment surveys are low. And critically, Zoetis has no exposure to Medicare pricing negotiations, which have created material headline risk for human pharmaceutical companies including some of its sector peers.

Management guided for 2%–5% organic revenue growth in 2026, with recovery expected in the second half. The international segment surged 17% organically in Q1, which partially offsets the U.S. companion animal decline. Next earnings report is scheduled for August 11. The current price represents either a value opportunity in a structurally sound business going through a product-cycle transition — or an early position in a name that has more clearing out to do. That is the honest framing. Full breakdown here before the August print.

For informational purposes only.